首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Report of ribosomal RNA methylase gene erm(B) in multidrug-resistant Campylobacter coli
【24h】

Report of ribosomal RNA methylase gene erm(B) in multidrug-resistant Campylobacter coli

机译:多重耐药性弯曲杆菌中核糖体RNA甲基化酶基因erm(B)的报道

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Campylobacter is a major foodborne enteric pathogen and macrolides are the drug of choice for the clinical therapy of campylobacteriosis. Macrolide resistance among Campylobacter compromises clinical treatment, is associated with adverse health events and is a significant public health concern. Here, we report the first identification of a horizontally transferrable macrolide resistance mechanism in porcine Campylobacter coli ZC113 that is mediated by a ribosomal RNA methylase, Erm(B). Methods: Horizontal transfer of a macrolide resistance determinant between C. coli and Campylobacter jejuni was performed by natural transformation. Whole-genome sequencing was initially used to identify the ribosomal methylase-encoding gene erm(B) in Campylobacter. Cloning of erm(B) into C. jejuni NCTC 11168 was performed to evaluate whether the erm(B) gene is responsible for high-level macrolide resistance in Campylobacter. Results: The erm(B) gene was identified in ZC113, conferred high-level resistance to macrolides and was associated with a chromosomal multidrug-resistant genomic island (MDRGI). The MDRGI probably originated from Gram-positive bacteria and was horizontally transferred between C. coli and C. jejuni via natural transformation. Furthermore, the erm(B)-positive isolate ZC113 was resistant to all clinically important antibiotics used for treating campylobacteriosis and is essentially multidrug-resistant Campylobacter. Conclusions: To the best of our knowledge, this is the first report of a horizontally transferable macrolide resistance mechanism in thermophilic Campylobacter. Surveillance of erm(B) and its associated MDRGI in both C. coli and C. jejuni is urgently warranted.
机译:目的:弯曲杆菌是一种主要的食源性肠道病原体,大环内酯类药物是弯曲杆菌病临床治疗的首选药物。弯曲杆菌中大环内酯类药物的耐药性损害了临床治疗,与不良健康事件相关,并且是重大的公共卫生问题。在这里,我们报道了由核糖体RNA甲基化酶Erm(B)介导的猪弯曲杆菌ZC113中可水平转移的大环内酯类耐药机制的首次鉴定。方法:通过自然转化在大肠杆菌和空肠弯曲菌之间进行大环内酯类抗性决定簇的水平转移。最初使用全基因组测序来鉴定弯曲杆菌中核糖体甲基化酶编码基因erm(B)。将erm(B)克隆到空肠弯曲杆菌NCTC 11168中,以评估erm(B)基因是否对弯曲杆菌的高水平大环内酯类耐药产生作用。结果:在ZC113中鉴定到erm(B)基因,赋予其对大环内酯类药物的高水平抗性,并与染色体多药耐药基因组岛(MDRGI)相关。 MDRGI可能起源于革兰氏阳性细菌,并通过自然转化在大肠杆菌和空肠弯曲杆菌之间水平转移。此外,erm(B)阳性分离株ZC113对用于治疗弯曲杆菌病的所有临床上重要的抗生素均具有耐药性,并且本质上是具有多重耐药性的弯曲杆菌。结论:据我们所知,这是嗜热弯曲杆菌水平可转移的大环内酯类耐药机制的首次报道。迫切需要在大肠杆菌和空肠弯曲杆菌中监测erm(B)及其相关的MDRGI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号